EXEL vs PTGX
Exelixis vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
65
Buy
| Metric | EXEL | PTGX |
|---|
| AI Score |
67
|
65
|
| Price |
$51.30
|
$148.25
|
| P/E Ratio |
15.60×
|
121.74×
|
| ROE |
36.2%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
99.9%
|
| Debt / Equity |
0.09×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
68.1
|
| Beta |
0.422
|
1.794
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus PTGX.
EXEL leads by 2 points.
EXEL scores 67/100 (Buy) versus PTGX at 65/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical